Biomolecular pathogenesis of borderline ovarian tumors: Focusing target discovery through proteogenomics

Current Cancer Drug Targets

Volumn 10, Issue 1, 2010, Pages 107-116

  Vergara, D ^a   Tinelli, A ^b   Martignago, R ^c   Malvasi, A ^d   Chiuri, V E ^e   Leo, G ^e  

^a NATIONAL NANOTECHNOLOGY LABORATORY   (Italy)

^b VITO FAZZI HOSPITAL   (Italy)

^c UNIVERSITY OF SALENTO   (Italy)

^d Santa Maria Hospital   (Italy)

^e Oncological Hospital   (Italy)

Author keywords

Borderline ovarian tumors; Ovarian cancer; Tumors of low malignant potential

Indexed keywords

ACTIVIN A; AQUAPORIN 5; B RAF KINASE; CD24 ANTIGEN; CLAUDIN 1; CLAUDIN 2; CLAUDIN 3; CLAUDIN 4; CLAUDIN 5; EPIDERMAL GROWTH FACTOR RECEPTOR; EPIDERMAL GROWTH FACTOR RECEPTOR 2; EPIDERMAL GROWTH FACTOR RECEPTOR 3; EPIDERMAL GROWTH FACTOR RECEPTOR 4; GLUCOSE TRANSPORTER 1; K RAS PROTEIN; MELANOMA ANTIGEN 4; MIGRATION INHIBITION FACTOR; PROTEIN P53; SYNDECAN 1; TRANSCRIPTION FACTOR RUNX3; UVOMORULIN;

BORDERLINE OVARY TUMOR; CARCINOGENESIS; CHROMOSOMAL INSTABILITY; GENE EXPRESSION; GENE MUTATION; GENOMICS; HISTOPATHOLOGY; HUMAN; MICROSATELLITE INSTABILITY; MOLECULAR DYNAMICS; ONCOGENE K RAS; OVARY TUMOR; PATHOGENESIS; PROGNOSIS; REVIEW; RISK FACTOR; TUMOR GROWTH; TUMOR RECURRENCE;

CYSTADENOCARCINOMA, SEROUS; DNA METHYLATION; FEMALE; GENE EXPRESSION REGULATION, NEOPLASTIC; GENOMIC INSTABILITY; GENOMICS; HUMANS; MUTATION; OVARIAN NEOPLASMS; PRECANCEROUS CONDITIONS; PROTEOMICS; PROTO-ONCOGENE PROTEINS; PROTO-ONCOGENE PROTEINS B-RAF; RAS PROTEINS; TUMOR MARKERS, BIOLOGICAL; TUMOR SUPPRESSOR PROTEIN P53;

EID: 77950455557     PISSN: 15680096     EISSN: None     Source Type: Journal    
DOI: 10.2174/156800910790980269     Document Type: Review

References (104)

1. Ozols, R. F.; Bookman, M. A.; Connolly, D. C.; Daly, M. B.; Godwin, A. K.; Schilder, R. J.; Xu, X.; Hamilton, T. C. Focus on epithelial ovarian cancer. Cancer Cell. 2004, 5, 19-24.
2. Taylor, H. C. Malignant and semimalignant tumors of the ovary. Surg. Gynecol. Obstet. 1929, 48, 204-230.
3. Tinelli, R.; Malzoni, M.; Cosentino, F.; Perone, C.; Tinelli, A.; Malvasi, A.; Cicinelli, E. Feasibility, safety, and efficacy of conservative laparoscopic treatment of borderline ovarian tumors. Fertil. Steril. 2009, 92, 736-741.
4. Tinelli, A.; Malvasi, A.; Leo, G.; Vergara, D.; Martignago, R.; Pellegrino, M.; Pisanò, M.; Cinieri, S.; Lorusso, V. Borderline ovarian tumors: new insights and old challenge. J. Chin. Clin. Med. 2009, 4, 343-352.
5. Bell, D. A.; Longacre, T. A.; Prat, J.; Kohn, E. C.; Soslow, R. A.; Ellenson, L. H.; Malpica, A.; Stoler, M. H.; Kurman, R. J. Serous borderline (low malignant potential, atypical proliferative) ovarian tumors: workshop perspectives. Hum. Pathol. 2004, 35, 934-948.
6. Tinelli A.; Malvasi, A.; Lorusso, V.; Chiuri, V. E.; Cinieri, S.; Vergara, D.; Martignago, R.; Vergari, U.; Pisanò, M.; Leo, G. Biogenomic pathways in breast and ovarian malignancies: clinical and surgical workflow focused on tailoring procedures. In: Ovesen K, Matthiesen U. DNA: fingerprinting, sequencing and chips. Nova Science Publishers ed., Hauppauge, NY, USA, 2010, vol. 6, pp. 119-132.
7. Tinelli, F. G.; Tinelli, R.; La Grotta, F.; Tinelli, A.; Cicinelli, E.; Schönauer, M. M. Pregnancy outcome and recurrence after conservative laparoscopic surgery for borderline ovarian tumors. Acta Obstet. Gynecol. Scand. 2007, 86, 81-87.
8. Tinelli, R.; Tinelli, A.; Tinelli, F. G.; Cicinelli, E.; Malvasi, A. Conservative surgery for borderline ovarian tumors: a review. Gynecol. Oncol. 2006, 100, 185-191.
9. Kaern, J.; Tropé, C. G.; Abeler, V. M. A retrospective study of 370 borderline tumors of the ovary treated at the Norwegian Radium Hospital from 1970 to 1982. A review of clinicopathologic features and treatment modalities. Cancer 1993, 71, 1810-1820.
10. Buttin, B. M.; Herzog, T. J.; Powell, M. A.; Rader, J. S.; Mutch, D. G. Epithelial ovarian tumors of low malignant potential: the role of microinvasion. Obstet. Gynecol. 2002, 99, 11-17.
11. Sherman, M. E.; Mink, P. J.; Curtis, R.; Cote, T.; Brooks, S.; Hartge, P.; Devesa, S. Survival among women with borderline ovarian tumors and ovarian carcinoma: a population-based analysis. Cancer 2004, 100, 1045-1052.
12. Longacre, T. A.; McKenney, J. K.; Tazelaar, H. D.; Kempson, R. L.; Hendrickson, M. R. Ovarian serous tumors of low malignant potential (borderline tumors): outcome-based study of 276 patients with long-term (> or =5-year) follow-up. Am. J. Surg. Pathol. 2005, 29, 707-723.
13. Ren, J.; Peng, Z.; Yang, K. A clinicopathologic multivariate analysis affecting recurrence of borderline ovarian tumors. Gynecol. Oncol. 2008, 110, 162-167.
14. Prat, J.; De Nictolis, M. Serous borderline tumors of the ovary: a long-term follow-up study of 137 cases, including 18 with a micropapillary pattern and 20 with microinvasion. Am. J. Surg. Pathol. 2002, 26, 1111-1128.
15. Eichhorn, J. H.; Bell, D. A.; Young, R. H.; Scully, R. E. Ovarian serous borderline tumors with micropapillary and cribriform patterns: a study of 40 cases and comparison with 44 cases without these patterns. Am. J. Surg. Pathol. 1999, 23, 397-409.
16. Snider, D.; Stuart, G.; Nation, J. Evaluation of surgical staging in stage I low malignant potential ovarian tumours. Gynecol. Oncol. 1991, 40, 129-132.
17. Bell, D. A. Ovarian surface epithelial-stromal tumors. Hum. Pathol. 1991, 22, 750-762.
18. Tinelli, A.; Vergara, D.; Martignago, R.; Leo, G.; Pisanò, M.; Malvasi, A. An outlook on ovarian cancer and borderline ovarian tumors: focus on genomic and proteomic findings. Curr. Genomics 2009, 4, 240-249.
19. Tinelli, A.; Vergara, D.; Martignago, R.; Leo, G.; Malvasi, A.; Tinelli, R.; Marsigliante, S.; Maffia, M.; Lorusso, V. Ovarian cancer biomarkers: a focus on genomic and proteomic findings. Curr. Genomics 2007, 8, 335-342.
20. Momparler, R. L. Cancer epigenetics. Oncogene 2003, 22, 6479-6483.
21. Su, H. Y.; Lai, H. C.; Lin, Y. W.; Chou, Y. C.; Liu, C. Y.; Yu, M. H. An epigenetic marker panel for screening and prognostic prediction of ovarian cancer. Int. J. Cancer 2008, 124, 387-393.
22. Tam, K. F.; Liu, V. W.; Liu, S. S.; Tsang, P. C.; Cheung, A. N.; Yip, A. M.; Ngan, H. Y. Methylation profile in benign, borderline and malignant ovarian tumors. J. Cancer Res. Clin. Oncol. 2007, 133, 331-341.
23. Cheng, P.; Schmutte, C.; Cofer, K. F.; Felix, J. C.; Yu, M. C.; Dubeau, L. Alterations in DNA methylation are early, but not initial, events in ovarian tumorigenesis. Br. J. Cancer 1997, 75, 396-402.
24. Körner, M.; Burckhardt, E.; Mazzucchelli, L. Different proportions of aneusomic cells in ovarian inclusion cysts associated with serous borderline tumours and serous high-grade carcinomas support different pathogenetic pathways. J. Pathol. 2005, 207, 20-26.
25. Tangir, J.; Loughridge, N. S.; Berkowitz, R. S.; Muto, M. G.; Bell, D. A.; Welch, W. R.; Mok, S. C. Frequent Microsatellite Instability in Epithelial Borderline Ovarian Tumors. Cancer Res. 1996, 56, 2501-2505.
26. Singer, G.; Kurman, R. J.; Chang, H. W.; Cho, S. K.; Shih, IeM. Diverse tumorigenic pathways in ovarian serous carcinoma. Am. J. Pathol. 2002, 160, 1223-1228.
27. Staebler, A.; Heselmeyer-Haddad, K.; Bell, K.; Riopel, M.; Perlman, E.; Ried, T.; Kurman, R. J. Micropapillary serous carcinoma of the ovary has distinct patterns of chromosomal imbalances by comparative genomic hybridization compared with atypical proliferative serous tumors and serous carcinomas. Hum. Pathol. 2002, 33, 47-59.
28. Osterberg, L.; Akeson, M.; Levan, K.; Partheen, K.; Zetterqvist, B. M.; Brännström, M.; Horvath, G. Genetic alterations of serous borderline tumors of the ovary compared to stage I serous ovarian carcinomas. Cancer Genet. Cytogenet. 2006, 167, 103-108.
29. Hsu, C. Y.; Kurman, R. J.; Vang, R.; Wang, T. L.; Baak, J.; Shih, IeM. Nuclear size distinguishes low- from high-grade ovarian serous carcinoma and predicts outcome. Hum. Pathol. 2005, 36, 1049-1054.
30. Mok, S. C.; Bell, D. A.; Knapp, R. C.; Fishbaugh, P. M.; Welch, W. R.; Muto, M. G.; Berkowitz, R. S.; Tsao, S. W. Mutation of K-ras protooncogene in human ovarian epithelial tumors of borderline malignancy. Cancer Res. 1993, 53, 1489-1492.
31. Ichikawa, Y.; Nishida, M.; Suzuki, H.; Yoshida, S.; Tsunoda, H.; Kubo, T.; Uchida, K.; Miwa, M. Mutation of K-ras protooncogene is associated with histological subtypes in human mucinous ovarian tumors. Cancer Res. 1994, 54, 33-35.
32. Gemignani, M. L.; Schlaerth, A. C.; Bogomolniy, F.; Barakat, R. R.; Lin, O.; Soslow, R.; Venkatraman, E.; Boyd, J. Role of KRAS and BRAF gene mutations in mucinous ovarian carcinoma. Gynecol. Oncol. 2003, 90, 378-381.
33. Oliva, E.; Sarrió, D.; Brachtel, E. F.; Sánchez- Estévez, C.; Soslow, R. A.; Moreno-Bueno, G.; Palacios, J. High frequency of β-catenin mutations in borderline endometrioid tumours of the ovary. J. Pathol. 2006, 208, 708-713.
34. Ho, C. L.; Kurman, R. J.; Dehari, R.; Wang, T. L.; Shih, IeM. Mutations of BRAF and KRAS Precede the Development of Ovarian Serous Borderline Tumors. Cancer Res. 2004, 64, 6915-6918.
35. Mayr, D.; Hirschmann, A.; Löhrs, U.; Diebold, J. KRAS and BRAF mutations in ovarian tumors: A comprehensive study of invasive carcinomas, borderline tumors and extraovarian implants. Gynecol. Oncol. 2006, 103, 883-887.
36. Shih, IeM.; Kurman, R. J. Ovarian tumorigenesis: a proposed model based on morphological and molecular genetic analysis. Am. J. Pathol. 2004, 164, 1511-1518.
37. Singer, G.; Stöhr, R.; Cope, L.; Dehari, R.; Hartmann, A.; Cao, D. F.; Wang, T. L.; Kurman, R. J.; Shih, IeM. Patterns of p53 mutations separate ovarian serous borderline tumors and low- and high-grade carcinomas and provide support for a new model of ovarian carcinogenesis: a mutational analysis with immunohistochemical correlation. Am. J. Surg. Pathol. 2005, 29, 218-224.
38. Leitao, M. M.; Soslow, R. A.; Baergen, R. N.; Olvera, N.; Arroyo, C.; Boyd, J. Mutation and expression of the TP53 gene in early stage epithelial ovarian carcinoma. Gynecol. Oncol. 2004, 93, 301-306.
39. Lee, J. H.; Kang, Y. S.; Park, S. Y.; Kim, B. G.; Lee, E. D.; Lee, K. H.; Park, K. B.; Kavanagh, J. J. Wharton, J. T. p53 mutation in epithelial ovarian carcinoma and borderline ovarian tumor. Cancer Genet. Cytogenet. 1995, 85, 43-50.
40. Chan, W. Y.; Cheung, K. K.; Schorge, J. O.; Huang, L. W.; Welch, W. R.; Bell, D. A.; Berkowitz, R. S.; Mok, S. C. Bcl-2 and p53 protein expression, apoptosis, and p53 mutation in human epithelial ovarian cancers. Am. J. Pathol. 2000, 156, 409-417.
41. Marks, J. R.; Davidoff, A. M.; Kerns, B. J.; Humphrey, P. A.; Pence, J. C.; Dodge, R. K.; Clarke-Pearson, D. L.; Iglehart, J. D.; Bast, R. C. Jr.; Berchuck, A. Overexpression and mutation of p53 in epithelial ovarian cancer. Cancer Res. 1991, 51, 2979-2984.
42. Ortiz, B. H.; Ailawadi, M.; Colitti, C.; Muto, M. G.; Deavers, M.; Silva, E. G.; Berkowitz, R. S.; Mok, S. C.; Gershenson, D. M. Second primary or recurrence? Comparative patterns of p53 and K-ras mutations suggest that serous borderline ovarian tumors and subsequent serous carcinomas are unrelated tumors. Cancer Res. 2001, 61, 7264-7267.
43. Skomedal, H.; Kristensen, G. B.; Abeler, V. M.; Børresen-Dale, A. L.; Tropé, C.; Holm, R. TP53 protein accumulation and gene mutation in relation to overexpression of MDM2 protein in ovarian borderline tumours and stage I carcinomas. J. Pathol. 1997, 181, 158-165.
44. Wang, Y.; Helland, A.; Holm, R.; Skomedal, H.; Abeler, V. M.; Danielsen, H. E.; Tropé, C. G.; Børresen-Dale, A. L.; Kristensen, G. B. TP53 mutations in early-stage ovarian carcinoma, relation to long-term survival. Br. J. Cancer 2004, 90, 678-685.
45. Bonome, T.; Lee, J. Y.; Park, D. C.; Radonovich, M.; Pise-Masison, C.; Brady, J.; Gardner, G. J.; Hao, K.; Wong, W. H.; Barrett, J. C.; Lu, K. H.; Sood, A. K.; Gershenson, D. M.; Mok, S. C.; Birrer, M. J. Expression profiling of serous low malignant potential, low-grade, and high-grade tumors of the ovary. Cancer Res. 2005, 65, 10602-10612.
46. Marchini, S.; Mariani, P.; Chiorino, G.; Marrazzo, E.; Bonomi, R.; Fruscio, R.; Clivio, L.; Garbi, A.; Torri, V.; Cinquini, M.; Dell'Anna, T.; Apolone, G.; Broggini, M.; D'Incalci, M. Analysis of Gene Expression in Early-Stage Ovarian Cancer. Clin. Cancer Res. 2008, 14, 7850-7860.
47. Meinhold-Heerlein, I.; Bauerschlag, D.; Hilpert, F.; Dimitrov, P.; Sapinoso, L. M.; Orlowska-Volk, M.; Bauknecht, T.; Park, T. W.; Jonat, W.; Jacobsen, A.; Sehouli, J.; Luttges, J.; Krajewski, M.; Krajewski, S.; Reed, J. C.; Arnold, N.; Hampton, G. M. Molecular and prognostic distinction between serous ovarian carcinomas of varying grade and malignant potential. Oncogene 2005, 24, 1053-1065.
48. Chien, J.; Fan, J. B.; Bell, D. A.; April, C.; Klotzle, B.; Ota, T.; Lingle, W. L.; Gonzalez Bosquet, J.; Shridhar, V.; Hartmann, L. C. Analysis of gene expression in stage I serous tumors identifies critical pathways altered in ovarian cancer. Gynecol. Oncol. 2009, 114, 3-11.
49. Biade, S.; Marinucci, M.; Schick, J.; Roberts, D.; Workman, G.; Sage, E. H.; O'Dwyer, P. J.; Livolsi, V. A.; Johnson, S. W. Gene expression profiling of human ovarian tumours. Br. J. Cancer 2006, 95, 1092-1100.
50. Fogel, M.; Friederichs, J.; Zeller, Y.; Husar, M.; Smirnov, A.; Roitman, L.; Altevogt, P.; Sthoeger, Z. M. CD24 is a marker for human breast carcinoma. Cancer Lett. 1999, 143, 87-94.
51. Aigner, S.; Ruppert, M.; Hubbe, M.; Sammar, M.; Sthoeger, Z.; Butcher, E. C.; Vestweber, D.; Altevogt, P. Heat stable antigen (mouse CD24) supports myeloid cell binding to endothelial and platelet P-selectin. Int. Immunol. 1995, 7, 1557-1565.
52. Kristiansen, G.; Denkert, C.; Schluns, K. CD24 is expressed in ovarian cancer and is a new independent prognostic marker of patient survival. Am. J. Pathol. 2002, 161, 1215-1221.
53. Choi, Y.; Kim, S.; Shin, Y.; Dahl, E.; Pilarsky, C.; Hauptmann, S. Cytoplasmic CD24 expression in advanced ovarian serous borderline tumors. Gynecol. Oncol. 2005, 97, 379-386.
54. Sagiv, E.; Starr, A.; Rozovski, U.; Khosravi, R.; Altevogt, P.; Wang, T.; Arber, N. Targeting CD24 for treatment of colorectal and pancreatic cancer by monoclonal antibodies or small interfering RNA. Cancer Res. 2008, 68, 2803-2812.
55. Thiery, J. P. Epithelial-mesenchymal transitions in tumour progression. Nat. Rev. Cancer 2002, 2, 442-454.
56. Geho, D. H.; Bandle, R. W.; Clair, T.; Liotta, L. A. Physiological Mechanisms of Tumor-Cell Invasion and Migration. Physiology 2005, 20, 194-200.
57. Leporatti, S.; Vergara, D.; Zacheo, A.; Vergaro, V.; Maruccio, G.; Cingolani, R.; Rinaldi, R. Cytomechanical and topological investigation of MCF-7 cells by Scanning Force Microscopy. Nanotechnology 2009, 20, 55103.
58. Sundfeldt, K.; Piontkewitz, Y.; Ivarsson, K.; Nilsson, O.; Hellberg, P.; Brännström, M.; Janson, P. O.; Enerback, S.; Hedin, L. Ecadherin expression in human epithelial ovarian cancer and normal ovary. Int. J. Cancer 1997, 74, 275-280.
59. Daraï, E.; Scoazec, J. Y.; Walker-Combrouze, F.; Mlika-Cabanne, N.; Feldmann, G.; Madelenat, P.; Potet, F. Expression of cadherins in benign, borderline, and malignant ovarian epithelial tumors: a clinicopathologic study of 60 cases. Hum. Pathol. 1997, 28, 922-928.
60. Reddy, P.; Liu, L.; Ren, C.; Lindgren, P.; Boman, K.; Shen, Y.; Lundin, E.; Ottander, U.; Rytinki, M.; Liu, K. Formation of E-Cadherin-Mediated Cell-Cell Adhesion Activates Akt and Mitogen Activated Protein Kinase via Phosphatidylinositol 3 Kinase and Ligand-Independent Activation of Epidermal Growth Factor Receptor in Ovarian Cancer Cells. Mol. Endocrinol. 2005, 19, 2564-2578.
61. Auersperg, N.; Pan, J.; Grove, B. D.; Peterson, T.; Fisher, J.; Maines-Bandiera, S.; Somasiri, A.; Roskelley, C. D. E-cadherin induces mesenchymal-to-epithelial transition in human ovarian surface epithelium. Proc. Natl. Acad. Sci. USA 1999, 96, 6249-6254.
62. Batlle, E.; Sancho, E.; Franci, C.; Dominguez, D.; Monfar, M.; Baulida, J.; Garcia De Herreros, A. The transcription factor Snail is a repressor of E-cadherin gene expression in epithelial tumour cells. Nat. Cell. Biol. 2000, 2, 84-89.
63. Bolos, V.; Peinado, H.; Perez-Moreno, M. A.; Fraga, M. F.; Esteller, M.; Cano, A. The transcription factor Slug represses E-cadherin expression and induces epithelial to mesenchymal transitions: a comparison with Snail and E47 repressors. J. Cell Sci. 2003, 116, 499-511.
64. Yoshida, J.; Horiuchi, A.; Kikuchi, N.; Hayashi, A.; Osada, R.; Ohira, S.; Shiozawa, T.; Konishi, I. Changes in the expression of E-cadherin repressors, Snail, Slug, SIP1, and Twist, in the development and progression of ovarian carcinoma: the important role of Snail in ovarian tumorigenesis and progression. Med. Mol. Morphol. 2009, 42, 82-91.
65. Cho, E. Y.; Choi, Y.; Chae, S. W.; Sohn, J. H.; Ahn, G. H. Immunohistochemical study of the expression of adhesion molecules in ovarian serous neoplasms. Pathol. Int. 2006, 56, 62-70.
66. Zavadil, J.; Böttinger, E. P. TGF-beta and epithelial-tomesenchymal transitions. Oncogene 2005, 24, 5764-5774.
67. Lim, R.; Ahmed, N.; Borregaard, N.; Riley, C.; Wafai, R.; Thompson, E. W.; Quinn, M. A.; Rice, G. E. Neutrophil gelatinase-associated lipocalin [NGAL] an early-screening biomarker for ovarian cancer: NGAL is associated with epidermal growth factor-induced epithelio-mesenchymal transition. Int. J. Cancer 2007, 120, 2426-2434.
68. Do, T.; Kubba, L. A.; Du, H.; Sturgis, C. D.; Woodruff, T. K. Transforming Growth Factor-β1, Transforming Growth Factor-β2, and Transforming Growth Factor-β3 Enhance Ovarian Cancer Metastatic Potential by Inducing a Smad3-Dependent Epithelial-to-Mesenchymal Transition. Mol. Cancer Res. 2008, 6, 695-705.
69. Do, T.; Kubba, L. A.; Antenos, M.; Rademaker, A. W.; Sturgis, C. D.; Woodruff, T. K. The role of activin A and Akt/GSK signaling in ovarian tumor biology. Endocrinology 2008, 149, 3809-3816.
70. Colomiere, M.; Ward, A. C.; Riley, C.; Trenerry, M. K.; Cameron-Smith, D.; Findlay, J.; Ackland, L.; Ahmed, N. Cross talk of signals between EGFR and IL-6R through JAK2/STAT3 mediate epithelial-mesenchymal transition in ovarian carcinomas. Br. J. Cancer 2009, 100, 134-144.
71. Colomiere, M.; Findlay, J.; Ackland, L.; Ahmed, N. Epidermal growth factor-induced ovarian carcinoma cell migration is associated with JAK2/STAT3 signals and changes in the abundance and localization of α6β1 integrin. Int. J. Biochem. Cell. Biol. 2008, 27, 1034-1045.
72. Burke, W. M.; Jin, X.; Lin, H. J.; Huang, M.; Liu, R.; Reynolds, R. K.; Lin, J. Inhibition of constitutively active Stat3 suppresses growth of human ovarian and breast cancer cells. Oncogene 2001, 20, 7925-7934.
73. Bijman, M. N.; van Berkel, M. P.; van Nieuw Amerongen, G. P.; Boven, E. Interference with actin dynamics is superior to disturbance of microtubule function in the inhibition of human ovarian cancer cell motility. Biochem. Pharmacol. 2008, 76, 707-716.
74. dos Remedios, C. G.; Chhabram, D.; Kekic, M.; Dedova, I. V.; Tsubakihara, M.; Berry, D. A.; Nosworthy, N. J. Actin Binding Proteins: Regulation of Cytoskeletal Microfilaments. Physiol. Rev. 2003, 83, 433-473.
75. Pawlak, G.; Helfman, D. M. Cytoskeletal changes in cell transformation and tumorigenesis. Curr. Opin. Genet. Dev. 2001, 11, 41-47.
76. Machesky, L. M. Lamellipodia and filopodia in metastasis and invasion. FEBS Lett. 2008, 582, 2102-2111.
77. Sahai, E.; Marshall, C. J. RHO-GTPases and cancer. Nat. Rev. Cancer 2002, 2, 133-142.
78. Thériault, B. L.; Shepherd, T. G.; Mujoomdar, M. L.; Nachtigal, M. W. BMP4 induces EMT and Rho GTPase activation in human ovarian cancer cells. Carcinogenesis 2007, 28, 1153-1162.
79. Horiuchi, A.; Imai, T.; Wang, C.; Ohira, S.; Feng, Y.; Nikaido, T.; Konishi, I. Up-regulation of small GTPases, RhoA and RhoC, is associated with tumor progression in ovarian carcinoma. Lab. Invest. 2003, 83, 861-870.
80. Sawada, K.; Morishige, K.; Tahara, M.; Kawagishi, R.; Ikebuchi, Y.; Tasaka, K.; Murata, Y. Alendronate inhibits lysophosphatidic acid-induced migration of human ovarian cancer cells by attenuating the activation of rho. Cancer Res. 2002, 62, 6015-6020.
81. Hashimoto, K.; Morishige, K.; Sawada, K.; Tahara, M.; Shimizu, S.; Sakata, M.; Tasaka, K.; Murata, Y. Geranylgeranylacetone inhibits lysophosphatidic acid-induced invasion of human ovarian carcinoma cells in vitro. Cancer 2005, 103, 1529-1536.
82. Hashimoto, K.; Morishige, K.; Sawada, K.; Ogata, S.; Tahara, M.; Shimizu, S.; Sakata, M.; Tasaka, K.; Kimura, T. Geranylgeranylacetone inhibits ovarian cancer progression in vitro and in vivo. Biochem. Biophys. Res. Commun. 2007, 356, 72-77.
83. Kwiatkowski, D. J. Functions of gelsolin: motility, signaling, apoptosis, cancer. Cur. Opin. Cell. Biol. 1999, 11, 103-108.
84. Noske, A.; Denkert, C.; Schober, H.; Sers, C.; Zhumabayeva, B.; Weichert, W.; Dietel, M.; Wiechen, K. Loss of Gelsolin expression in human ovarian carcinomas. Eur. J. Cancer 2005, 41, 461-469.
85. Kureishy, N.; Sapountzi, V.; Prag, S.; Anilkumar, N.; Adams, J. C. Fascins, and their roles in cell structure and function. Bioessays 2002, 24, 350-361.
86. Hu, W.; McCrea, P. D.; Deavers, M.; Kavanagh, J. J.; Kudelka, A. P.; Verschraegen, C. F. Increased expression of fascin, motility associated protein, in cell cultures derived from ovarian cancer and in borderline and carcinomatous ovarian tumors. Clin. Exp. Metastasis 2000, 18, 83-88.
87. Kostopoulou, E.; Daponte, A.; Terzis, A.; Nakou, M.; Chiotoglou, I.; Theodosiou, D.; Chatzichristodoulou, C.; Messinis, I. E.; Koukoulis, G. Fascin in ovarian epithelial tumors. Histol. Histopathol. 2008, 23, 935-944.
88. Kabukcuoglu, S.; Oner, U.; Ozalp, S. S.; Bildirici, K.; Yalcin, O. T.; Colak, E. The role of actin bundling protein fascin in the progression of ovarian neoplasms. Eur. J. Gynaecol. Oncol. 2006, 27, 171-176.
89. Lin, C. K.; Su, H. Y.; Tsai, W. C.; Sheu, L. F.; Jin, J. S. Association of cortactin, fascin-1 and epidermal growth factor receptor (EGFR) expression in ovarian carcinomas: correlation with clinicopathological parameters. Dis. Markers 2008, 25, 17-26.
90. Daponte, A.; Kostopoulou, E.; Minas, M.; Koukoulis, G.; Messinis, I. E. Prognostic significance of fascin expression in advanced poorly differentiated serous ovarian cancer. Anticancer Res. 2008, 28, 1905-1910.
91. Bengtsson, S.; Krogh, M.; Szigyarto, C. A.; Uhlen, M.; Schedvins, K.; Silfverswärd, C.; Linder, S.; Auer, G.; Alaiya, A.; James, P. Large-Scale Proteomics Analysis of Human Ovarian Cancer for Biomarkers. J. Proteome Res. 2007, 6, 1440-1450.
92. Hagemann, T.; Robinson, S. C.; Thompson, R. G.; Charles, K.; Kulbe, H.; Balkwill, F. R. Ovarian cancer cell-derived migration inhibitory factor enhances tumor growth, progression, and angiogenesis. Mol. Cancer Ther. 2007, 6, 1993-2002.
93. Davies, E. J.; Blackhall, F. H.; Shanks, J. H.; David, G.; McGown, A. T.; Swindell, R.; Slade, R. J.; Martin-Hirsch, P.; Gallagher, J. T.; Jayson, G. C. Distribution and clinical significance of Heparan sulfate proteoglycans in ovarian cancer. Clin. Cancer Res. 2004, 10, 5178-5186
94. Yang, J.; Shi, Y.; Cheng, Q.; Deng, L. Expression and localization of aquaporin-5 in the epithelial ovarian tumors. Gynecol. Oncol. 2005, 100, 294-299.
95. Nevadunsky, N. S.; Barbieri, J. S.; Kwong, J.; Merritt, M. A.; Welch, W. R.; Berkowitz, R. S.; Mok, S. C. RUNX3 protein is overexpressed in human epithelial ovarian cancer. Gynecol. Oncol. 2009, 112, 325-330.
96. Cantuaria, G.; Magalhaes, A.; Penalver, M.; Angioli, R.; Braunschweiger, P.; Gomez-Marin, O.; Kanhoush, R.; Gomez-Fernandez, C.; Nadji, M. Expression of GLUT-1 Glucose Transporter in Borderline and Malignant Epithelial Tumors of the Ovary. Gynecol. Oncol. 2000, 79, 33-37.
97. Steffensen, K. D.; Waldstrøm, M.; Andersen, R. F.; Olsen, D. A.; Jeppesen, U.; Knudsen, H. J.; Brandslund, I.; Jakobsen, A. Protein levels and gene expressions of the epidermal growth factor receptors, HER1, HER2, HER3 and HER4 in benign and malignant ovarian tumors. Int. J. Oncol. 2008, 33, 195-204.
98. Steffensen, K. D.; Waldstrøm, M.; Olsen, D. A.; Corydon, T.; Lorentzen, K. A.; Knudsen, H. J.; Jeppesen, U.; Brandslund, I.; Jakobsen, A. Mutant Epidermal Growth Factor Receptor in Benign, Borderline, And Malignant Ovarian Tumors. Clin. Cancer Res. 2008, 14, 3278-3282.
99. Yakirevich, E.; Sabo, E.; Lavie, O.; Mazareb, S.; Spagnoli, G. C.; Resnick, M. B. Expression of the MAGE-A4 and NY-ESO-1 Cancer-Testis Antigens in Serous Ovarian Neoplasms. Clin. Cancer Res. 2003, 9, 6453-6460.
100. Zhu, Y.; Brännström, M.; Janson, P. O.; Sundfeldt, K. Differences in expression patterns of the tight junction proteins,claudin 1, 3, 4 and 5, in human ovarian surface epithelium as compared to epithelia in inclusion cysts and epithelial ovarian tumours. Int. J. Cancer 2006, 118, 1884-1891.
101. Agarwal, R.; Whang, D. H.; Alvero, A. B.; Visintin, I.; Lai, Y.; Segal, E. A.; Schwartz, P.; Ward, D.; Rutherford, T.; Mor, G. Macrophage migration inhibitory factor expression in ovarian cancer. Am. J. Obstet. Gynecol. 2007, 196, 348.
102. Lemaire, R.; Menguellet, S. A.; Stauber, J.; Marchaudon, V.; Lucot, J. P.; Collinet, P.; Farine, M. O.; Vinatier, D.; Day, R.; Ducoroy, P.; Salzet, M.; Fournier, I. Specific MALDI imaging and profiling for biomarker hunting and validation: fragment of the 11S proteasome activator complex, Reg alpha fragment, is a new potential ovary cancer biomarker. J. Proteome Res. 2007, 6, 4127-4134.
103. Caprioli, R. M.; Farmer, T. B.; Gile, J. Molecular imaging of biological samples: localization of peptides and proteins using MALDI-TOF MS. Anal. Chem. 1997, 69, 4751-4760.
104. Lemaire, R.; Desmons, A.; Tabet, J. C.; Day, R.; Salzet, M.; Fournier, I. Direct analysis and MALDI imaging of formalin-fixed, paraffin-embedded tissue sections. J. Proteome Res. 2007, 6, 1295-1305.